China is emerging as a global frontrunner in patenting artificial intelligence (AI) technologies for drug discovery, particularly in the field […]
Source
The pharmaceutical industry is a high-stakes arena where innovation, investment, and intellectual property (IP) protection intersect. One of the most […]
Source
The Power of Patience: Delaying Patents to Enhance Pharma Market Exclusivity Read Post »
Lipitor’s marketing strategy underwent a significant evolution as generic competition emerged, employing aggressive tactics to retain market share and brand […]
Source
How can pharmaceutical marketing evolve with generic entry? The example of Lipitor Read Post »
Patent Expirations and Generic Competition This week saw several major blockbuster drugs facing patent expirations, potentially opening the market for […]
Source
Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective management of drug patent portfolios requires strategic planning, ongoing evaluati…
Best Practices for Drug Patent Portfolio Management Read Post »
This is an example from the DrugPatentWatch AI Research Assistant, which is available with DrugPatentWatch subscriptions. The DrugPatentWatch AI Research Assistantuses sophisticated AI algorithms to understand and process your questions, delivering pre…
Introduction In the rapidly evolving landscape of pharmaceutical patent disputes in China, injunctive relief has emerged as a critical tool for patent holders. This legal remedy, which aims to halt infringement activities swiftly, plays a pivotal role …
The Double-Edged Sword: Opportunities and Challenges in China’s Patent Litigation System Read Post »
DrugChatter is an innovative AI-powered search and answer engine designed to revolutionize how we access and comprehend information. Harnessing the power of advanced natural language processing, DrugChatter provides concise, accurate, and contextually …
Introducing DrugChatter: Revolutionizing Information Access Read Post »
Introduction: The United States Patent and Trademark Office (USPTO) has recently released a comprehensive study on drug patents and exclusivity trends in the pharmaceutical industry. The report, titled “USPTO Drug Patent and Exclusivity Study Report,” …
The 505(b)(2) regulatory pathway provides an attractive avenue for drug developers to bring new products to market by leveraging existing data on approved drugs. This pathway allows modifications and improvements to be made to existing drugs, while pot…
Leveraging 505(b)(2) to Innovate Beyond Existing Drug Patents Read Post »